

## Curriculum Vitae

**Grit Barten-Neiner**, Dipl.-Chem., MBA

d.o.b. August 9th 1967, Rostock, Germany

Managing Director/CEO, CAPNETZ STIFTUNG, Hannover Medical School,

Carl-Neuberg-Str. 1, 30625, Hannover, Germany

Telephone: +49 (0)511 532 4434. E-Mail: [grit.barten@capnetz.de](mailto:grit.barten@capnetz.de)

### UNIVERSITY EDUCATION

1989-1996 Chemistry Diploma, University Bremen, Bremen

2011-2014 Master of Business Administration. FOM University of Applied Sciences, Bremen

### PROFESSIONAL POSITION

2001-2007 Altana Pharma Deutschland GmbH, Konstanz, Germany  
Pharmaceutical representative at out- and in-patient sector  
Regional Manager Sales Force Out-patient sector  
Head of Sales Force Hospital, Germany

2007-2008 Nycomed Deutschland GmbH, Konstanz  
Head of Sales Force Hospital, Germany

Since 2008 CAPNETZ STIFTUNG, Hannover, Germany  
Office at Hannover Medical School  
CEO/Managing Director

### SUPPORT (COORDINATION AND OVER ALL MANAGEMENT) and/or PI of RESEARCH PROJECTS

2001-2023 Public funded, BMBF/DZL, CAPNETZ as associated Partner of the German Lungcenter (DZL, Deutsches Zentrum für Lungenforschung), The CAPNETZ-Study

2009-2012 Public funded, BMBF, Clinical Performance of a Multiplex PCR-Based Detection System for a Comprehensive Panel of Respiratory Pathogens (The SYMP-ARI Study)

2011-2015 Public funded, BMBF, Consortium Project ZONNOSEN, Subproject: Prävalenz der Infektion mit Chlamydialen beim Menschen in Deutschland

2012-2019 Public funded, BMBF, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study

2014-2017 Funded by the European Commission, PREPARE, Consortium research project, WP4: Multi-centre European study of MAJOR Infectious Disease Syndromes Acute Respiratory Infections in Adults, WP5: Adaptive Platform Trial for Severe Community Acquired Pneumonia (AD-SCAP)

2015-2020 Public funded, BMBF/DZL, pedCAPNETZ – Development and detailed Characterization of a Cohort for Community Acquired Pneumonia (CAP) in Childhood and Adolescence  
2015-2019 Investigator-initiated national research project PROGNOSIS study – THE PROSPECTIVE GERMAN NON-CF BRONCHIECTASIS PATIENT REGISTRY

2017-2020 Public Funded, BMBF, POCT zur Unterscheidung bakterieller / viraler Infektionen der oberen Atemwege mittels zeitaufgelöster Fluoreszenz (BaViFlu)

2020-2022 Public Funded, BMBF, PROVID, Klinische, molekulare und funktionelle Biomarker für Prognose, Pathomechanismen und Behandlungsstrategien von COVID-19

- 2020-2022 pedCAPNETZ-COVID 19, Prospektive Beobachtungsstudie zu SARS-CoV2 Infektionen bei Kindern und Jugendlichen, funded by Novartis
- 2020-2022 Pediatric Airway Pathogen Incidence (PAPI) Study, funded by Sanofi Pasteur
- 2023-2025 Burden of disease and cost of illness for RSV and other pathogens in the outpatient setting (BUCOSS Study), funded by GSK
- 2024-2026 Burden of Disease and Cost of illness (BUCOSS) for RSV and other pathogens among Hospitalized adults, funded by GSK
- 2024-2027 Public funded DZL, HERLP-PCD, CREATING EVIDENCE FOR THE USE OF HYPERTONIC SALINE IN PEOPLE WITH PRIMARY CILIARY DYSKINESIA
- 2024-2027 Public funded BMG, No1Lost, Aufbau und Evaluation eines Kompetenznetzwerks Therapieadhärenz zur nachhaltigen Verbesserung der Therapieergebnisse bei multiresistenter Tuberkulose in Deutschland

## EXPERIENCE

- 2008-2018 Teaching Study Coordinators of CAPNETZ Study sites
- 2015-2018 Steering Committee Member PROGNOSIS Registry
- 2017-2018 Steering Committee Member pedCAPNETZ Network
- 2017 Lecturer at DFG Nachwuchsakademie „Klinische Studien in der Infektionsmedizin“

## PUBLICATION

Rajam G, Zhang Y, Antonello JM, Grant-Klein RJ, Cook L, Panemangalore R, Pham H, Cooper S, Steinmetz TD, Nguyen J, Pletz MW, **Barten-Neiner G**, Murphy RD, Rubinstein LJ, Nolan KM. Development and Validation of a Sensitive and Robust Multiplex Antigen Capture Assay to Quantify *Streptococcus pneumoniae* Serotype-Specific Capsular Polysaccharides in Urine. **mSphere** 2022; 7(4):e0011422. doi: [10.1128/msphere.00114-22](https://doi.org/10.1128/msphere.00114-22)

Pletz MW, Jensen AV, Bahrs C, Davenport C, Rupp J, Witzenrath M, **Barten-Neiner G**, Kolditz M, Dettmer S, Chalmers JD, Stolz D, Suttorp N, Aliberti S, Kuebler WM, Rohde G. Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. **Respir Res** 2022; 23(1):239. doi: [10.1186/s12931-022-02117-3](https://doi.org/10.1186/s12931-022-02117-3)

Schleenvoigt BT, Ankert J, **Barten-Neiner G**, Voit F, Suttorp N, Boesecke C, Hoffmann C, Stolz D, Pletz MW, Rohde G, Witzenrath M, Panning M, Essig A, Rupp J, Degen O, Stephan C; CAPNETZ Study Group. Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort. **Infection** 2024; 52(1):129-137. doi: [10.1007/s15010-023-02070-3](https://doi.org/10.1007/s15010-023-02070-3)

Dähne T, Bauer W, Essig A, Schaaf B, **Barten-Neiner G**, Spinner CD, Pletz MW, Rohde G, Rupp J, Witzenrath M, Panning M; Members of the CAPNETZ study group. Resurgence of common respiratory viruses in patients with community-acquired pneumonia (CAP)-A prospective multicenter study. **J Clin Virol** 2024; 173:105694. doi: [10.1016/j.jcv.2024.105694](https://doi.org/10.1016/j.jcv.2024.105694)

Julius C, Pletz MW, Rupp J, Witzenrath M, **Barten-Neiner G**, Rohde G. Pneumonia in the third year of the pandemic: one eye on the pathogens, the other on the host. **Am J Physiol Lung Cell Mol Physiol** 2022;323(5):L611-L614. doi: [10.1152/ajplung.00330.2022](https://doi.org/10.1152/ajplung.00330.2022)

Glöckner V, Pletz MW, Rohde G, Rupp J, Witzernath M, *Barten-Neiner G*, Kolditz M; CAPNETZ Study Group. Early post-discharge mortality in CAP: frequency, risk factors and a prediction tool. **Eur J Clin Microbiol Infect Dis** 2022; 41(4):621-630. doi: [10.1007/s10096-022-04416-5](https://doi.org/10.1007/s10096-022-04416-5)

Bahrs C, Kesselmeier M, Kolditz M, Ewig S, Rohde G, *Barten-Neiner G*, Rupp J, Witzernath M, Welte T, Pletz MW; CAPNETZ Study Group. A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany. **Eur Respir J** 2022; 59(2):2102432. doi: [10.1183/13993003.02432-2021](https://doi.org/10.1183/13993003.02432-2021)

Forstner C, Kolditz M, Kesselmeier M, Ewig S, Rohde G, *Barten-Neiner G*, Rupp J, Witzernath M, Welte T, Pletz MW; CAPNETZ study group. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia. **Vaccine** 2020; 38(5):1129-1136. doi: [10.1016/j.vaccine.2019.11.026](https://doi.org/10.1016/j.vaccine.2019.11.026).

Wetzke M, Schütz K, Kopp MV, Seidenberg J, Vogelberg C, Ankermann T, Happle C, Voigt G, Köster H, Illig T, Lex C, Schuster A, Maier R, Panning M, *Barten G*, Rohde G, Welte T, Hansen G. Pathogen spectra in hospitalised and non-hospitalised children with community-acquired pneumonia. **ERJ Open Res** 2023; 9(2):00286-2022. doi: [10.1183/23120541.00286-2022](https://doi.org/10.1183/23120541.00286-2022)

Wetzke M, Kopp MV, Seidenberg J, Vogelberg C, Ankermann T, Happle C, Voigt G, Köster H, Illig T, Lex C, Schuster A, Panning M, *Barten G*, Rohde G, Welte T, Hansen G; pedCAPNETZ Study Group. PedCAPNETZ - prospective observational study on community acquired pneumonia in children and adolescents. **BMC Pulm Med** 2019; 19(1):238. doi: [10.1186/s12890-019-1013-5](https://doi.org/10.1186/s12890-019-1013-5)